Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
Frequently asked questions
What sector does Newron Pharmaceuticals SpA (NWRN) operate in?
Newron Pharmaceuticals SpA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Newron Pharmaceuticals SpA (NWRN) current stock price?
As of the latest data, Newron Pharmaceuticals SpA stock price is CHF 12.94, with a previous close of CHF 11.72. Newron Pharmaceuticals SpA gained CHF 1.22 in the last trading session, representing a 10.41% increase.
What is Newron Pharmaceuticals SpA (NWRN) current market capitalization?
Newron Pharmaceuticals SpA market cap is approximately 269.23 million.
What is Newron Pharmaceuticals SpA (NWRN) Earnings Per Share (EPS)?
The trailing EPS is -CHF 0.62, and the forward EPS is CHF 0.80.
Does Newron Pharmaceuticals SpA (NWRN) pay dividends?
No. Newron Pharmaceuticals SpA does not pay a dividend.
When is Newron Pharmaceuticals SpA (NWRN) next earnings report?
Newron Pharmaceuticals SpA is expected to release its next earnings report on September 30, 2025.
What is Newron Pharmaceuticals SpA (NWRN) beta (volatility) score?
Newron Pharmaceuticals SpA has a beta of 0.734, indicating lower volatility than the overall market.
